FIELD: medicine, pharmacy.
SUBSTANCE: invention refers to medicine and is a transdermal pharmaceutical composition in the form of gel or patch that contains vardenafil, enhancer selected from the group consisting of sodium lauroamphoacetate, quaternium-60, izostearamidopropil morpholine lactate and combinations thereof, and a pharmaceutically acceptable excipient. The enhancer accelerates the kinetics of transdermal absorption of vardenafil. Vardenafil and enhancer are present in the composition in a ratio from 20:1 to 2:1 by weight. The invention also relates to the method of acceleration of the transdermal delivery of vardenafil.
EFFECT: invention provides transdermal delivery acceleration due to the vardenafil enhancer.
8 cl, 2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD AND IMPROVED PHARMACEUTICAL COMPOSITION FOR ACCELERATING THE TRANSDERMAL DELIVERY OF A PDE-5 INHIBITOR | 2016 |
|
RU2660353C2 |
| TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTERING TIROFIBAN | 2010 |
|
RU2539398C2 |
| TETRABENAZINE TRANSDERMAL DELIVERY DEVICE | 2019 |
|
RU2800536C2 |
| TRANSDERMAL PLASTER | 2011 |
|
RU2553350C2 |
| TRANSDERMAL DELIVERY OF LAZOPHOXIPHEN | 2001 |
|
RU2328276C2 |
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
| COMPOSITION COMPRISING PROBIOTIC BACTERIA OR COMPONENTS THEREOF, AND METHOD FOR USE THEREOF IN TREATING IMMUNE SKIN DISEASES | 2017 |
|
RU2699540C2 |
| TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | 2015 |
|
RU2713207C2 |
| PDE INHIBITORS AND THEIR COMBINATIONS FOR TREATMENT OF UROLOGIC DISORDERS | 2006 |
|
RU2435588C2 |
| DOSAGE FORMS CONTAINING DOPAMINE AGONISTS FOR PARENTERAL ADMINISTRATION | 2009 |
|
RU2532347C2 |
